Related Experiment Video

Updated: May 5, 2026

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.5K

New drugs in sarcomas

Juan Martin-Liberal1, Charlotte Benson, Ian Judson

  • 1The Royal Marsden Hospital, Sarcoma Unit , Fulham Road SW3 6JJ, London , UK +44 20 7808 2200 ; +44 20 7808 2113 ; juan.martin@rmh.nhs.uk.

Expert Opinion on Pharmacotherapy
|November 26, 2013
PubMed
Abstract

Insights

New sarcoma drugs show promise, with ongoing trials focusing on specific molecular targets to improve patient outcomes. Further research into targeted therapies is crucial for advancing sarcoma treatment and enhancing prognosis.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Adult sarcomas are rare cancers with poor prognoses and limited effective treatments.
  • Advances in understanding molecular pathology have led to targeted drug development.
  • Some novel compounds have demonstrated successful outcomes in clinical trials.

Purpose of the Study:

  • To review the latest clinical trials for adult sarcoma treatments.
  • To discuss the biological rationale behind emerging sarcoma therapies.
  • To highlight promising drugs in earlier stages of development.

Main Methods:

  • Comprehensive review of reported Phase III clinical trials.
  • Discussion of pazopanib, regorafenib, muramyl tripeptide (MTP), and ridaforolimus.
  • Exploration of early-stage drugs including CDK4/MDM2 inhibitors, cediranib, eribulin, and crizotinib.

Main Results:

  • Phase III trials of pazopanib, regorafenib, MTP, and ridaforolimus have been evaluated.
  • Several novel targeted therapies are in earlier developmental stages.
  • Biological rationale supports the use of these investigational compounds.

Conclusions:

  • Future clinical trials must target specific sarcoma subtypes and molecular alterations for accurate drug identification.
  • Focusing on targeted therapies is expected to improve patient prognosis in the coming years.
  • Continued research into novel compounds holds potential for advancing sarcoma treatment.

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.3K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.6K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.2K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K